antimicrobial resistance
BioMérieux, Boehringer Ingelheim, Evotec Launch €40M AMR-Targeted Joint Venture
Called Aurobac Therapeutics, the joint venture will develop new antimicrobial drugs and companion diagnostics.
Illumina Acquires IDbyDNA
The firms have had an alliance for the past two years and market a respiratory pathogen panel.
Branded InSignia, the patented technology will first be incorporated into a gonorrhea antimicrobial susceptibility assay, followed by a point-of-care test.
In the collaboration's next phase, the companies plan to develop means to counter AMR through repurposing current antibiotics.
BioMérieux Joint Infection Panel Gets FDA De Novo Authorization
The 39-target panel runs on FilmArray systems and tests for 31 pathogens implicated in most acute joint infections as well as eight antimicrobial resistance genes.